0001654954-18-007091.txt : 20180628
0001654954-18-007091.hdr.sgml : 20180628
20180628162556
ACCESSION NUMBER: 0001654954-18-007091
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180626
FILED AS OF DATE: 20180628
DATE AS OF CHANGE: 20180628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILLS STEPHEN T
CENTRAL INDEX KEY: 0001103883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15543
FILM NUMBER: 18925666
MAIL ADDRESS:
STREET 1: PALATIN TECHNOLOGIES, INC.
STREET 2: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC
CENTRAL INDEX KEY: 0000911216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954078884
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 609-495-2200
MAIL ADDRESS:
STREET 1: 4B CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: INTERFILM INC
DATE OF NAME CHANGE: 19930825
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2018-06-26
0000911216
PALATIN TECHNOLOGIES INC
PTN
0001103883
WILLS STEPHEN T
PALATIN TECHNOLOGIES, INC.
4B CEDAR BROOK DRIVE
CRANBURY
NJ
08512
false
true
false
false
Executive VP and CFO/COO
Common Stock
2018-06-26
4
A
false
135000
0
A
3384489
D
Common Stock
2018-06-26
4
A
false
303000
0
A
3687489
D
Stock Option (right to buy)
1
2018-06-26
4
A
false
454000
0
A
2019-06-26
2028-06-26
Common Stock
454000
454000
D
Stock Option (right to buy)
.85
2018-06-26
4
A
false
135000
0
A
2018-06-26
2027-12-12
Common Stock
135000
135000
D
Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 12, 2017, vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc.
Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 50% June 26, 2019 and as to the remaining shares on June 26, 2020. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc.
Options vest at the rate of 25% per year, starting on June 26, 2019.
Vesting of performance condition stock option grant, made December 12, 2017, which vested in part on June 26, 2018, upon certification by the Compensation Committee that a defined performance objective as to 30% of the target number of share units had been achieved, the acceptance for filing by the U.S. Food and Drug Administration of a New Drug Application for bremelanotide for hypoactive sexual desire disorder in premenopausal women during the defined performance period.
/s/ Stephen T. Wills, by Stephen A. Slusher, Attorney-In-Fact
2018-06-28